Comparison of RT-qPCR and ddPCR for miR-371a-3p profiling in malignant germ cell tumors, indicating better performance with RT-qPCR.
Previous work has shown that circulating miR-371a-3p has higher sensitivity and specificity than current biomarkers for malignant germ cell tumors (MGCT). Here, the performance of two methods commonly used to measure miR-371a-3p levels was compared: reverse transcription quantitative PCR (RT-qPCR) and droplet-digital PCR (ddPCR). Samples from the University of Texas Southwestern (UTSW) Medical Center and the University of Cambridge (UoC) were evaluated using both RT-qPCR and ddPCR, as per current protocols (RT-qPCR) or standard manufacturer’s recommendations (ddPCR). Data were available for 70 patients, comprising 36 patients with MGCT and 34 controls (non-malignant GCT, non-GCT cancer, and non-cancer controls). The performance of the two assays was compared using receiver operating characteristic (ROC) curves and the area under the curve (AUC). Raw miR-371a-3p Cq values (RT-qPCR) were generally lower (i.e., miR-371a-3p was more abundant) and the number of positive droplets (ddPCR) higher for MGCT patients compared with controls. The AUC was 0.94 (95% CI: 0.90, 0.99) and 0.82 (0.70, 0.93) when using RT-qPCR and ddPCR, respectively. Thus, RT-qPCR had better classification performance compared with ddPCR in the current cohort, supporting the continued use of RT-qPCR in standard clinical practice. Further investigation is required to optimize ddPCR before it should be considered for clinical adoption.
No takes yet. Share an insight, caveat, or question.
Matthew Murray (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: